Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
To increase awareness, outline strategies, and offer guidance on the recommended management of
immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy.
A multidisciplinary, multi-organizational panel of experts in medical oncology, dermatology, gastro-
enterology, rheumatology, pulmonology, endocrinology, urology, neurology, hematology, emergency
medicine, nursing, trialist, and advocacy was convened to develop the clinical practice guideline.
Guideline development involved a systematic review of the literature and an informal consensus
process. The systematic review focused on guidelines, systematic reviews and meta-analyses,
randomized controlled trials, and case series published from 2000 through 2017.
The systematic review identified 204 eligible publications. Much of the evidence consisted of
systematic reviews of observational data, consensus guidelines, case series, and case reports. Due
to the paucity of high-quality evidence on management of immune-related adverse events, rec-
ommendations are based on expert consensus.